AVEO Pharmaceuticals, Inc. Sustainability Profile
AVEO Pharmaceuticals, Inc., a prominent player in the biopharmaceutical industry, is headquartered in the United States. Founded in 2001, the company has made significant strides in developing innovative therapies for cancer treatment, focusing on targeted therapies and biomarker-driven approaches. With a strong presence in major operational regions, AVEO is dedicated to advancing its core products, including the FDA-approved drug FOTIVDA® (tivozanib), which is designed for the treatment of advanced renal cell carcinoma. This unique product stands out due to its selective inhibition of vascular endothelial growth factor (VEGF) receptors, offering a differentiated approach in oncology. AVEO's commitment to research and development has positioned it as a leader in the oncology sector, with notable achievements in clinical trials and partnerships that enhance its market presence. The company continues to strive for excellence in delivering effective cancer therapies to improve patient outcomes.
DitchCarbon Score
How does AVEO Pharmaceuticals, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
AVEO Pharmaceuticals, Inc.'s score of 65 is higher than 80% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
AVEO Pharmaceuticals, Inc., headquartered in the US, currently does not report specific carbon emissions data, as indicated by the absence of emissions figures. The company is a current subsidiary of LG Chem, Ltd., which means that any climate commitments or emissions data may be inherited from its parent organisation. As of now, AVEO Pharmaceuticals has not established its own reduction targets or climate pledges. However, it is important to note that the climate initiatives and performance metrics may be influenced by LG Chem, Ltd., which has its own sustainability strategies and targets. Given the lack of specific emissions data and reduction initiatives from AVEO Pharmaceuticals, stakeholders may need to look to LG Chem, Ltd. for insights into the broader climate commitments and performance of the corporate family.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|
| Scope 1 | 5,270,020,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 |
| Scope 2 | 4,140,987,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 |
| Scope 3 | - | 0,000,000,000 | - | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 00,000,000,000 | 00,000,000,000 |
How Carbon Intensive is AVEO Pharmaceuticals, Inc.'s Industry?
How Carbon Intensive is AVEO Pharmaceuticals, Inc.'s Location?
AVEO Pharmaceuticals, Inc.'s Scope 3 Categories Breakdown
AVEO Pharmaceuticals, Inc.'s Scope 3 emissions, which increased by 69% last year and increased significantly since 2018, demonstrating supply chain emissions tracking. Most of their carbon footprint comes from suppliers and value chain emissions, with Scope 3 emissions accounting for 67% of total emissions under the GHG Protocol, with "End-of-Life Treatment of Sold Products" being the largest emissions source at 13% of Scope 3 emissions.
Top Scope 3 Categories
AVEO Pharmaceuticals, Inc.'s Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
AVEO Pharmaceuticals, Inc. has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
